Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.
Related Keywords
Georgia , United States , Kevin Kalinsky , Ribociclib Kisqali , , Winship Cancer Institute , Emory University , Ribociclib , Switch Endocrine Therapy , Maintain Trial , Hormone Receptor Positive Breast Cancer , Her2 Negative Breast Cancer , Breast Cancer , Journal Of Clinical Oncology ,
comparemela.com © 2020. All Rights Reserved.